Research Article
Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133+ Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy
Table 5
Stability of CD133+ cells in physiological saline (+5% HSA) at 4°C in three ATMP-CD133 batches.
| Batch # | Parameter | Time points | (thawing) | h | h | h |
| PTC-CD133-098 | Viability (%) | 97.00 | 91.68 | 90.76 | 91.07 | Purity (% CD133+ cells) | 92.76 | nd | 92.73 | 90.59 |
| PTC-CD133-116 | Viability (%) | 90.72 | 94.23 | 94.07 | 93.47 | Purity (% CD133+ cells) | 84.69 | nd | 85.98 | 85.86 |
| PTC-CD133-068 | Viability | 88.70 | 90.00 | 94.70 | 92.68 | Purity (% CD133+ cells) | 89.15 | nd | 89.41 | 87.89 |
|
|
nd: not done.
|